Adaptive Designs for Confirmatory Clinical Trials with Subgroup Selection

REFERENCES

• et al. ( 2008 ). Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer . Journal of Clinical Oncology 26 : 1626 – 1634 .
   PubMed Web of Science ®Google Scholar
• Armitage , P. , McPherson , C. K. , Rowe , B. C. ( 1969 ). Repeated significance tests on accumulating data . Journal of the Royal Statistical Society Series A 132 : 235 – 244 .
   Web of Science ®Google Scholar
• Benda , N. , Branson , M. , Maurer , W. , Friede , T. ( 2010 ). Aspects of modernizing drug development using scenario planning and evaluation . Drug Information Journal 44 : 299 – 315 .
   Web of Science ®Google Scholar
• Bowden , J. , Glimm , E. ( 2008 ). Unbiased estimation of selected treatment means in two-stage trials . Biometrical Journal 50 : 515 – 527 .
   PubMed Web of Science ®Google Scholar
• Brannath , W. , Posch , M. , Bauer , P. ( 2002 ). Recursive combination tests . Journal of the American Statistical Association 97 : 236 – 244 .
   Web of Science ®Google Scholar
• Brannath , W. , Zuber , E. , Branson , M. , Bretz , F. , Gallo , P. , Posch , M. , Racine-Poon , A. ( 2009 ). Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology . Statistics in Medicine 28 : 1445 – 1463 .
   PubMed Web of Science ®Google Scholar
• Burton , A. , Altman , D. G. , Royston , P. , Holder , R. L. (2006). The design of simulation studies in medical statistics. Statistics in Medicine 25:4279–4292.
   PubMed Web of Science ®Google Scholar
• Carreras , M. , Brannath , W. ( 2012 ). Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection . Statistics in Medicine 32 : 1677 – 1690 .
   PubMed Web of Science ®Google Scholar
• Clisant , S. , Clermont , A. , Adenis , A. , Penel , N. ( 2012 ). Inflation in the number of eligibility criteria for industry-sponsored phase ii cancer clinical trial: Illustration over a 20-year period . Contemporary Clinical Trials 33 : 459 .
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use . ( 2007a ). Concept Paper on the Need for a Guideline on the Use of Subgroup Analyses in Randomised Controlled Trials. EMA/CHMP/EWP/117211/2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090116.pdf
   Google Scholar
• Committee for Medicinal Products for Human Use . ( 2007b ). Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003616.pdf
   Google Scholar
• Food and Drug Administration . ( 2010 ). Guidance for Industry—Adaptive Design Clinical Trials for Drugs and Biologics. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf (accessed January 1, 2013) .
   Google Scholar
• Freidlin , B. , Simon , R. ( 2005 ). Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients . Clinical Cancer Research 11 : 7872 – 7828 .
   PubMed Web of Science ®Google Scholar
• Friede , T. , Henderson , R. ( 2009 ). Exploring changes in treatment effects across design stages in adaptive trials . Pharmaceutical Statistics 8 : 62 – 72 .
   PubMed Web of Science ®Google Scholar
• Friede , T. , Nicholas , R. , Stallard , N. , Todd , S. , Parsons , N. , Valds-Mrquez , E. , Chataway , J. ( 2010 ). Refinement of the clinical scenario evaluation framework for assessment of competing development strategies with an application to multiple sclerosis . Drug Information Journal 44 : 713 – 718 .
   Web of Science ®Google Scholar
• Friede , T. , Parsons , N. , Stallard , N. ( 2012 ). A conditional error function approach for subgroup selection in adaptive clinical trials . Statistics in Medicine 31 : 4309 – 4320 .
   PubMed Web of Science ®Google Scholar
• Gallo , P. ( 2006a ). Confidentiality and trial integrity issues for adaptive designs . Drug Information Journal 40 : 445 – 450 .
   Web of Science ®Google Scholar
• Gallo , P. ( 2006b ). Operational challenges in adaptive design implementation . Pharmaceutical Statistics 5 : 119 – 124 .
   PubMed Web of Science ®Google Scholar
• Gallo , P. , Chuang-Stein , C. , Dragalin , V. , Gaydos , B. , Krams , M. , Pinheiro , J. ( 2006 ). Adaptive designs in clinical drug development—An executive summary of the PhRMA working group . Journal of Biopharmaceutical Statistics 16 : 275 – 283 .
   PubMed Web of Science ®Google Scholar
• Grouin , J. M. , Coste , M. , Lewis , J. ( 2005 ). Sungroup analyses in randomized clinical trials: Statistical and regulatory issues . Journal of Biopharmaceutical Statistics 15 : 869 – 882 .
   PubMed Web of Science ®Google Scholar
• Hochberg , Y. ( 1988 ). A sharper Bonferroni procedure for multiple tests of significance . Biometrika 75 : 800 – 802 .
   Web of Science ®Google Scholar
• ICH E9 Expert Working Group . ( 1999 ). Statistical principles for clinical trials: ICH harmonized tripartite guideline . Statistics in Medicine 18 : 1905 – 1942 .
   PubMed Web of Science ®Google Scholar
• Jenkins , M. , Stone , A. , Jennison , C. ( 2011 ). An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints . Pharmaceutical Statistics 10 : 347 – 356 .
   PubMed Web of Science ®Google Scholar
• Jennison , C. , Turnbull , B. W. ( 2000 ). Group Sequential Methods With Applications to Clinical Trials . Boca Raton , FL : Chapman & Hall .
   Google Scholar
• Jiang , W. , Freidlin , B. , Simon , R. ( 2007 ). Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect . Journal of the National Cancer Institute 99 : 1036 – 1043 .
   PubMed Web of Science ®Google Scholar
• Lan , K. K. G. , DeMets , D. L. (1983). Discrete sequential boundaries for clinical trials. Biometrika 70:659–663.
   Web of Science ®Google Scholar
• Lehmacher , W. , Wassmer , G. ( 1999 ). Adaptive sample size calculations in group sequential trials . Biometrics 55 : 1286 – 1290 .
   PubMed Web of Science ®Google Scholar
• Magnusson , B. P. , Turnbull , B. W. ( 2013 ). Group sequential enrichment design incorporating subgroup selection . Statistics in Medicine 32 ( 16 ): 2695 – 2714 .
   PubMed Web of Science ®Google Scholar
• Millen , B. A. , Dmitrienko , A. , Truberg , S. , Shen , L. ( 2012 ). A statistical framework for decision making in confirmatory multipopulation tailoring clinical trials . Drug Information Journal 46 ( 6 ): 647 – 656 .
   Web of Science ®Google Scholar
• Müller , H.-H. , Schäfer , H. ( 2001 ). Adaptive group sequential designs for clinical trials: Combining the advantage of adaptive and of classical group sequential approaches . Biometrics 57 : 886 – 891 .
   PubMed Web of Science ®Google Scholar
• Parsons , N. , Friede , T. , Todd , S. , Valdes-Marquez , E. , Chataway , J. , Nicholas , R. , and Stallard , N. ( 2012 ). An R package for implementing simulations for seamless phase II/III clinical trials using early outcomes for treatment selection . Computational Statistics and Data Analysis 56 : 1150 – 1160 .
   Web of Science ®Google Scholar
• Prenen , H. , Tejpar , S. , Cutsem , E. V. ( 2010 ). New strategies for treatment of kras mutant metastatic colorectal cancer . Clinical Cancer Research 16 ( 11 ): 2921 – 2926 .
   PubMed Web of Science ®Google Scholar
• Quinlan , J. A. , Krams , M. ( 2006 ). Implementing adaptive designs: logistical and operational considerations . Drug Information Journal 40 : 437 – 444 .
   Web of Science ®Google Scholar
• Rosenblum , M. , Van Der Laan , M. J. ( 2011 ). Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment . Biometrika 98 : 845 – 860 .
   PubMed Web of Science ®Google Scholar
• Simes , R. J. ( 1986 ). An improved Bonferroni procedure for multiple test of significance . Biometrika 73 : 751 – 754 .
   Web of Science ®Google Scholar
• Song , Y. , Chi , Y. H. ( 2007 ). A method for testing a prespecified subgroup in clinical trials . Statistics in Medicine 26 ( 19 ): 3535 – 3549 .
   Google Scholar
• Spiessens , B. , Debois , M. ( 2010 ). Adjusted significance levels for subgroup analyses in clinical trials . Contemporary Clinical Trials 31 : 647 – 656 .
   PubMed Web of Science ®Google Scholar
• Stallard , N. , Friede , T. ( 2010 ). Efficiency of adaptive designs . In: Chow , S.-C. , Pong , A. , eds. Handbook of Adaptive Designs in Pharmaceutical and Clinical Development . Boca Raton , FL : Taylor & Francis .
   Google Scholar
• Stallard , N. , Todd , S. ( 2005 ). Point estimates and confidence regions for sequential trials involving selection . Journal of Statistical Planning and Inference 135 : 402 – 419 .
   Web of Science ®Google Scholar
• Steinvorth , S. , Röver , C. , Schneider , S. , Nicholas , R. , Straube , S. , Friede , T. ( 2013 ). Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: Systematic review and meta-regression . Multiple Sclerosis Journal 19 : 1580 – 1586 .
   PubMed Web of Science ®Google Scholar
• Van Cutsem , E. , Peeters , M. , Siena , S. , Humblet , Y. , Hendlisz , A. , Neyns , B. , Canon , J.-L. , Van Laethem , J.-L. , Maurel , J. , Richardson , G. , Wolf , M. , Amado , R. G. ( 2007 ). Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer . Journal of Clinical Oncology 25 : 1658 – 1664 .
   PubMed Web of Science ®Google Scholar
• Wang , S.-J. , Hung , H. M. J. , O'Neill , R. T. ( 2009 , April ). Adaptive patient enrichment designs in therapeutic trials . Biometrical Journal 51 : 358 – 374 .
   PubMed Web of Science ®Google Scholar
• Wang , S.-J. , O'Neill , R. T. , Hung , H. M. J. ( 2007 ). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset . Pharmaceutical Statistics 6 : 227 – 244 .
   PubMed Web of Science ®Google Scholar
• Zhao , Y. D. , Dmitrienko , A. , Tamura , R. ( 2010 ). Design and analysis considerations in clinical trials with a sensitive subpopulation . Statistics in Biopharmaceutical Research 2 : 72 – 83 .
   Web of Science ®Google Scholar